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Introduction: Seizures refractory to third-line therapy are also labeled super-refractory status epilepticus (SRSE).
These seizures are extremely difficult to control and associated with poor outcome. We aimed to characterize
efficacy and side-effects of continuous infusions of pentobarbital (cIV-PTB) treating SRSE.
Methods: We retrospectively reviewed continuous electroencephalography (cEEG) reports for all adults with RSE
treated with cIV-PTB between May 1997 and April 2010 at our institution. Patients with post-anoxic SE and those
receiving cIV-PTB for reasons other than RSE were excluded. We collected baseline information, cEEG findings,
side-effects and functional outcome at discharge and one year.
Results: Thirty one SRSE patients treated with cIV-PTB for RSE were identified. Mean age was 48 years old
(interquartile range (IQR) 28,63), 26% (N = 8) had a history of epilepsy. Median SE duration was 6.5 days (IQR 4,11)
and the mean duration of cIV-PTB was 6 days (IQR 3,14). 74% (N = 23) presented with convulsive SE. Underlying
etiology was acute symptomatic seizures in 52% (N = 16; 12/16 with encephalitis), remote 30% (N = 10), and unknown
16% (N = 5). cIV-PTB controlled seizures in 90% (N = 28) of patients but seizures recurred in 48% (N = 15) while weaning
cIV-PTB, despite the fact that suppression-burst was attained in 90% (N = 28) of patients and persisted >72 hours
in 56% (N = 17). Weaning was successful after adding phenobarbital in 80% (12/15 of the patients with withdrawal
seizures). Complications during or after cIV-PTB included pneumonia (32%, N = 10), hypotension requiring pressors
(29%, N = 9), urinary tract infection (13%, N = 4), and one patient each with propylene glycol toxicity and cardiac arrest.
One-third (35%, N = 11) had no identified new complication after starting cIV-PTB. At one year after discharge,
74% (N = 23) were dead or in a state of unresponsive wakefulness, 16% (N = 5) severely disabled, and 10% (N = 3)
had no or minimal disability. Death or unresponsive wakefulness was associated with catastrophic etiology
(p = 0.03), but none of the other collected variables.
Conclusions: cIV-PTB effectively aborts SRSE and complications are infrequent; outcome in this highly refractory
cohort of patients with devastating underlying etiologies remains poor. Phenobarbital may be particularly helpful
when weaning cIV-PTB.* Correspondence: jc1439@columbia.edu
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Seizures do not respond to first- and second-line therapy
in 9 to 40% [1-4] of patients with status epilepticus (SE).
This condition, known as refractory status epilepticus
(RSE), is associated with high morbidity [3-6] and is typ-
ically treated with anesthetic agents such as midazolam
or propofol [7]. Among these patients, 10 to 15% [4] fail
to respond to third-line therapy, and are considered to
have super-refractory SE (SRSE) [8]. These patients are
not well-studied, and in the absence of randomized
clinical trials treatment is controversial [9]. Continuous
intravenous (IV) infusions of pentobarbital (cIV-PTB),
a mainstay of RSE treatment for the past 50 years, have
been used less frequently as third-line therapy in favor
of midazolam or propofol. However, many protocols
recommend cIV-PTB for treatment of RSE refractory to
midazolam or propofol infusions [7,10]. We sought to
describe the use of cIV-PTB in patients with SRSE.
More specifically, we aimed to assess the efficacy of
cIV-PTB in terminating seizures, the occurrence of
withdrawal seizures, and the safety of using cIV-PTB in
the modern era of ICU care.
Methods
In this retrospective cohort study, patients with SE
admitted to Columbia University between May 1997 and
April 2010 were identified from continuous electroen-
cephalography (cEEG) reports. All adults with SRSE
monitored with cEEG and treated with cIV-PTB were
included in the study. Patients with post-anoxic SE or
those receiving cIV-PTB for reasons other than RSE
were excluded. Medical records were reviewed for clinical
details. The Institutional Review Board of Columbia-
Presbyterian Medical Center [11] approved this study and
waived the need for informed consent as it was a retro-
spective chart review study.
Definitions
RSE was defined as ongoing or recurrent seizures with-
out recovery of consciousness or return to baseline for
at least 30 minutes, and no response to first- and
second-line anti-epileptic drugs (AED) [7]. SRSE was
defined as ongoing or recurrent SE 24 h or more after
starting continuous infusion midazolam or propofol, and
included cases in which SE recurred upon reduction or
withdrawal of anesthesia [8]. PTB failure was defined as
a change to another AED due to failure of seizure control
despite anesthetic doses of cIV-PTB (doses of at least
1 mg/kg/h) or intolerability to PTB side effects. With-
drawal seizures were defined as the recurrence of seizures
during or within 48 h after tapering or withdrawal of
cIV-PTB [11,12]. SE etiology was classified as acute
symptomatic, remote symptomatic, progressive symp-
tomatic or idiopathic/cryptogenic. We also identifiedpatients with so-called catastrophic underlying etiology
if the life expectancy due to the underlying etiology was
likely less than 90 days. Seizure semiology was classified
as generalized convulsive or non convulsive, assessed
according to the earliest description prior to treatment
administration. The onset of SE was considered to be the
beginning of clinical seizure activity or a significant or sud-
den decline in neurologic function. Termination of SE was
defined as cessation of seizure activity on cEEG, regardless
of recovery of consciousness, without seizure recurrence
for at least 48 h after cessation of cIV-PTB. The levels of
AEDs were checked for all patients and confirmed to be in
a therapeutic range before starting cIV-PTB.
Patient management
EEG monitoring was performed for all patients at least
24 h prior to initiation of cIV-PTB and continued through
the weaning period except for patients who died before
completion of treatment. Patients with SE were treated
according to previously published institutional protocols
[13-15]. SE treatment was evaluated according to current
international guidelines and considered adequate if it
included intravenous administration of at least one benzo-
diazepine, plus phenytoin (PHT), levetiracetam (LEV)
or valproate (VPA), and was followed by continuous IV
infusion of midazolam (cIV-MDZ) or propofol (cIV-PRO).
Pentobarbital was administered as a 10 to 15 mg/kg loading
dose followed by continuous infusion of 0.5 to 4.0 mg/kg/h
and the dose was adjusted to achieve seizure control often
resulting in a suppression-burst pattern (SBP) on cEEG.
Data acquisition
Demographic data, medical history including prior epilepsy,
admission neurologic findings, SE etiology and semiology,
medication history prior to admission and medications
given in the hospital (specifically AEDs, including doses
and levels), cEEG findings, and hospital complications
(including potential side-effects from SE therapy: hypo-
tension requiring pressors administration or modification,
arrhythmia, myocardial infarct, pulmonary embolism, acid-
osis, fluid overload, and multiorgan failure) were recorded.
Data were collected through analysis of discharge sum-
maries, clinical notes, and laboratory results. We recorded
functional outcome at discharge and at 1 year, which
was considered poor if the patient died, was in a state
of unresponsive wakefulness, or had severe disability
(Glasgow outcome scale (GOS) 1 to 3) and good if the
patient had no or minimal disability (GOS 4 to 5). As
part of a larger study, data were also collected on patients
with RSE. These were used as a comparison group.
Statistics
Data were analyzed using commercially available soft-
ware (STATA version 11, College Station, TX, USA).
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test or the Fisher exact test, as appropriate. Continuous
variables were compared using the two-tailed t-test or
Mann-Whitney U-test for non-normally distributed data.
After identifying variables associated with outcome in the
univariate analysis we performed a binary logistic regres-
sion analysis to identify independent outcome predictors.
Results
Demographics
During the study period, 147 patients presented with
RSE, 21% (31/147) of whom fulfilled criteria for SRSE
treated with cIV-PTB during cEEG. In the SRSE group,
mean age was 48+/−20 years and 56% (17/31) were female
(see Table 1). Of the patients, 26% (8/31) had a history
of epilepsy, including two patients with Lennox-Gastaut
and one patient with cortical dysplasia. Initial seizure
semiology was convulsive in almost two thirds and non
convulsive in one third of SRSE patients. Of the patients
with acute etiology, 75% (12/31) had encephalitis: 26%
(8/31) had catastrophic etiologies including 13% (4/31)
with complicated astrocytoma (World Health OrganizationTable 1 Demographic and etiology
SRSE n = 31 RS
Age, years1 48 (+/-20) 6
Women, n (%) 17 (55)
Race, n (%)
White 15 (48)
Non white 16 (52)




Intracerebral hemorrhage 1 (3)
Stroke 1 (3)
Toxic-metabolic 1 (3)






Catastrophic etiology, n (%) 8 (26)
Length of SE, days2 6.5 (4, 11)
Type of SE, n (%)
Convulsive SE 23 (74)
NCSE 8 (26)
Data are given as number (n) (%), 1mean (+/- SD), or 2median (IQR). Catastrophic etiolo
The odds ratio for encephalitis associated with SRSE was 2.91 (1.08, 7.85) after correctin
non-convulsive status epilepticus; SE, status epilepticus; RSE, refractory status epilepticgrade III), 6% (2/31) with end-stage pancreatic cancer, and
one each with acute rejection of cardiac transplant and
meningeal carcinomatosis. In comparison, patients with
RSE who did not progress to SRSE were older (odds ratio
(OR) 0.96;CI 0.94-0.98), and more frequently had intracere-
bral hemorrhage (OR 0.09, 95% CI 0.01, 0.69). Patients with
SRSE were more likely to have encephalitis as the under-
lying etiology of SE (OR 4.35, 95% CI 1.71, 11.09).
AED treatment
All patients admitted with SRSE who received cIV-PTB
received first-, second-, and third-line therapy. Most
patients received a combination of a BZD and PHT (25/
31), followed by combinations of either BZD plus VPA
(4/31) or BZD plus LEV (2/31). Administered AED med-
ications included PHT/fosPHT in 80% (25/31), VPA in
67% (21/31), LEV in 61% (19/31), phenobarbital in 35%
(11/31), topiramate in 26% (8/31), lacosamide in 9% (3/31),
and ketamine in 9% (3/31) of patients. Midazolam was the
primary third-line choice in 94% of patients (29/31); 13 of
these later received propofol in addition to midazolam, and
the remainder received only propofol infusions (6%; 2/31).E n = 116 Odds ratio (95% CI) P-value
1 (+/-17) 0.96 (0.94, 0.98) 0.001*
78 (67)
52 (45) - -
64 (55) - -
38 (33)
70 (60) - -
13 (11) 4.35 (1.7, 11.09) 0.002*













gy is defined as life expectancy due to underlying etiology less than 90 days.
g for age. *Age and encephalitis were independently associated with SRSE. NCSE,
us; SRSE, super-refractory status epilepticus; NA, not applicable.
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tients had received at least four AEDs, up to a maximum
of eight AEDs.
cIV-PTB treatment
cIV-PTB was instituted within 6 days (IQR 2, 10) of the
onset of RSE. A maintenance dose of 0.5 to 1.7 mg/kg/h
of cIV-PTB was sufficient to maintain SBP in 64% of
patients, but increases of up to 2.0 to 3.7 mg/kg/h were
required for 36% of patients. The total duration of cIV-
PTB was 6 days (IQR 3, 14). PTB successfully stopped
SE in 90% (28/31) of the patients (Table 2). Two patients
with catastrophic etiologies and one with encephalitis
were considered PTB failures. Withdrawal seizures were
observed in 48% (15/31) of patients while attempting to
wean cIV-PTB. PTB was restarted in seven patients, all of
whom responded to restarting the medication. Phenobar-
bital was added in 12 of the 15 patients with withdrawal
seizures, which allowed successful weaning of cIV-PTB.
On cEEG, 90% (28/31) of patients achieved SBP, which
lasted more than 72 h in 56% of patients (17/31): 9% of
patients (3/31) developed complete EEG suppression
on initiation of cIV-PTB and dosing was reduced with
restoration of SBP. The overall length of the SBP correlated
with control of SRSE by PTB (P = 0.01). After termination
of SE, the SBP evolved most frequently to generalized
periodic discharges (GPDs) (46% of patients, n = 13) or
lateralized periodic discharges (LPDs) (16% of patients,Table 2 Anti-epileptic drug data
Variable Number (%) or
median (IQR)
Total number of patients 31 (100%)







Response to pentobarbital, patients 28 (90)
Length of pentobarbital drip, days 6 (3, 14)
Length of status epilepticus before
pentobarbital initiation, days
6 (2, 10)
Withdrawal seizure after interruption
of pentobarbital, patients
15 (48)
Withdrawal seizure requiring pentobarbital
restart, patients
7 (47)1
Phenobarbital to wean pentobarbital, patients 12 (80)1
1Percentages refer to number of patients with withdrawal seizure after
interruption of pentobarbital (n = 15). Response to pentobarbital is defined as
status epilepticus that was completely controlled by the therapy. Withdrawal
seizures are defined as recurrence of status epilepticus during or within 48 h
after the tapering or withdrawal of the therapy. AEDs, anti-epilectic drugs.n = 5). Patients without GPDs or LPDs had severe attenu-
ation (n = 5), persistent SBP (n = 1) or markedly slow
background (n = 2). Periodic discharges were associated
with a longer duration of PTB drip and a longer SBP
duration, but were not predictive of seizure relapse
after stopping cIV-PTB.
Safety
Of the 31 patients, 11 had no side effects related to
starting cIV-PTB (Table 3). Overall, ventilator-associated
pneumonia (32%) and hypotension requiring pressors
(32%) were the most frequently encountered complica-
tions during cIV-PTB treatment, followed by urinary tract
infection (13%), deep venous thrombosis (10%) and ileus
(10%). After initiation of cIV-PTB, the percentage of
patients requiring vasopressors increased from 13 to
32% (Figure 1). In all cases hypotension responded to fluid
administration and vasopressors, and did not require a
switch in cIV-AEDs: 15% of the patients (n = 7) had other
side effects such as neuropathy (n = 1), brain edema
and bleeding following brain biopsy (n = 1), and sepsis
which started before cIV-PTB (n = 3). One patient died
of post-anoxic encephalopathy after a bradycardic arrest
the day following cIV-PTB initiation, which occurred in
the setting of several episodes of bradycardia requiring
atropine administration prior to starting cIV-PTB. Another
patient with N-methyl-D-aspartate receptor encephalitis
developed propylene-glycol intoxication with severe acid-
osis, which resolved after cessation of cIV-PTB. All patients
in the study were mechanically ventilated prior to starting
cIV-PTB.
Outcome
The duration of SE was 6.5 days (IQR 4, 11): 74% (23/31)
of patients were referred from other hospitals, and 26%
(8/31) were primarily admitted at our institution. The
median ICU and hospital length of stay were 30 days
(IQR 16, 48; minimum 6, maximum 141 days) and
48 days (IQR 32, 94, minimum 11, maximum 310 days),
respectively. Catastrophic etiology as the underlyingTable 3 Side effects that developed in 31 patients during
treatment with pentobarbital
Side effects Number of patients (%)
None 11 (35)
Ventilator-associated pneumonia 10 (32)
Hypotension 10 (32)
Urinary tract infection 4 (13)
Deep venous thrombosis 3 (10)
Ileus 3 (10)
Other 7 (23)
Patients may have had more than one side effect.
Table 4 Outcome in 31 patients
Outcome at discharge Number of patients (%)
Outcome at discharge
Mortality (GOS 1) 13 (42)
GOS 1 to 2 20 (65)
GOS 3 10 (32)
GOS 4 to 5 1 (3)
Outcome at 1 year
Mortality (GOS 1) 18 (58)
GOS 1 to 2 23 (74)
GOS 3 5 (16)
GOS 4 to 5 3 (10)
GOS, Glasgow outcome scale.
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wakefulness at 1 year (P = 0.03). Age, duration of SE,
International League Against Epilepsy (ILAE) etiology or
SE type, and history of epilepsy were not associated with
outcome in our cohort of SRSE treated with cIV-PTB. Of
patients with catastrophic etiology, 75% (n = 5) were
seizure-free until the end of monitoring with cIV-PTB
(Table 4). However, two patients with catastrophic etiology
did not respond to cIV-PTB and were considered PTB
failures, both of whom died in the Neurological ICU. The
length of SBP did not correlate with outcome at discharge
or at one year. At discharge, 65% (n = 20) of patients were
dead or in a state of unresponsive wakefulness (GOS 1
to 2), 32% (n = 10) had severe disability, and 3% (n = 1)
had no or minimal disability (GOS 4 to 5). The mortality
at discharge was 42% (n = 13). At one year, 62% (n = 18)
had died, 15% (n = 5) were in a state of unresponsive
wakefulness and 10% (n = 3) had a GOS of 4 to 5.
Discussion
This study confirmed the high morbidity and mortality
of patients with SRSE treated with cIV-PTB; 42% were
dead at discharge and only 10% had favorable recovery
one year after discharge. However, favorable outcomes
were possible, and treatment-associated morbidity was
manageable in the ICU setting. Our cohort is unique as
it focused only on SRSE patients, whereas previously
published cohorts have been mostly a mix of patients
RSE and SRSE [1,4,12,16,17].
Efficacy
Of the studied SRSE patients, 90% were successfully treated
with cIV-PTB. In previous studies, the efficacy of cIV-PTB
in RSE ranged from 65% to 100%, but apart from a single
series reporting 40 patients, the others included fewer
than 18 patients [18-25]. Our results are consistent with
a meta-analysis of patients with RSE treated with PTB in
which 92% were seizure-free with PTB, compared toFigure 1 Vaspressors and pentobarbital. *Comparison before/during pen80% with midazolam or 73% with propofol [11]. In our
cohort, 90% of patients achieved SBP on cEEG, whereas
the prevalence of SBP after treatment with cIV-PTB in
prior studies has ranged from 38 to 60%. Most patients
treated with cIV-PTB in those studies had been treated
towards a goal of background suppression rather than
SBP [6,13,18,20-26]. As the efficacy of cIV-PTB treat-
ment in our cohort was comparable, we emphasize that
SBP may be a reasonable goal for PTB therapy, and in
particular, SBP lasting longer than 72 h may provide
superior seizure control.
While weaning from cIV-PTB, 48% of patients devel-
oped withdrawal seizures which is comparable to previous
descriptions (9 to 43%) [11,18-25,27]. At the same time,
restarting PTB interrupted seizures in all of our patients,
compared with 22% reported previously [8]. The addition
of PTB allowed successful weaning of cIV-PTB in 80% of
patients in our series. The high frequency of withdrawal
seizures, affecting almost half of the patients, stresses the
necessity for Ceeg, not only while starting cIV-PTB, but
also while weaning it in order to be able to detect and
treat these seizures as soon as possible.tobarbital (P = 0.016). §Comparison during/after pentobarbital (P = 0.001).
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In contrast to other reports, we found fewer side effects
in our cohort: 23% of patients did not have any side
effects attributable to treatment with cIV-PTB. Compared
with previously published data mostly on RSE, we found
ventilator-associated pneumonia in 32% (versus 65 to
69%) [3,5], hypotension requiring fluid and vasopres-
sors in 32% (versus 65 to 77%) [3,11], and urinary tract
infection in 13% (versus 42 to 46%) [3,5]. One patient
developed transient propylene glycol intoxication asso-
ciated with cIV-PTB infusion. However, none of these
complications influenced the outcomes, which is consist-
ent with previous descriptions [11] In previous RSE
studies including patients specifically treated with PTB,
hypotension was reported in 65 to 100%, but most of
these studies aimed to treat patients with a goal of EEG
background suppression [18,20,22-25]. The only adverse
event in this cohort was an isolated case of refractory
bradycardia, although the patient had several episodes
of bradycardia requiring atropine in the days before
PTB initiation. In a controlled setting such as the ICU,
the use of cIV-PTB to treat SRSE is safer than previously
described, and the concern for its side effects should not
limit its use except perhaps in circumstances of acute
hemodynamic instability.
Outcome
Mortality in our cohort was higher than previously
described for SE (42% versus 7 to 39%) [1,3-5] with a
wide range attributable to differences in study design
(retrospective versus prospective) and inclusion criteria.
Mortality rates of 42% reported in a prior cohort of
long-lasting RSE, and 48% in RSE patients treated with
cIV-PTB [1,3-5,11] are concordant with recent data that
RSE, and particularly SRSE, carries a worse outcome than
SE [4,16] This high mortality rate may reflect the selection
of patients with SRSE who constitute a relatively ill cohort
with higher prevalence of more malignant underlying
etiologies and highly refractory seizures [28]. In addition,
all our patients were mechanically ventilated, which in
itself has been associated with higher mortality [29]. Only
3% of patients had little or no disability at discharge,
improving to 10% at one year, confirming that SRSE is
a severe disease with poor functional outcome compared to
SE. Nevertheless, a small number of patients did well and
improved with time, even with SE lasting for several days.
None of the variables usually described to be related with
outcome, such as age, duration of SE, or a history of epi-
lepsy, correlated with outcome in our cohort [11,30-32].
The only variable predicting outcome in our series was a
catastrophic underlying etiology. Three-quarters of patients
with catastrophic etiology had control of SE with cIV-PTB,
however; it is most likely that the underlying disease was
the principle contributor to outcome in these cases. Ourseries was likely underpowered to detect differences in
mortality based on age, duration of SE, or a prior history
of epilepsy, but perhaps SRSE constitutes a subgroup of
patients in whom these established predictors of poor
outcome in RSE are less meaningful [5].
Limitations
Our cohort is one of the largest sets of patients with
SRSE treated with cIV-PTB, yet our analysis was still
underpowered to detect differences in outcome; as such,
we were unable to build a multivariate outcome model.
This was a retrospective single-center study that excluded
patients who received cIV-PTB prior to transfer where
it may have been given as third-line treatment and our
institutional protocol did not allow the use of cIV-PTB
as third-line therapy. This limits the generalizability of
our findings to RSE patients treated with cIV-PTB as
third-line treatment, as reported in much of the older
literature [18-25]. All RSE and SRSE patients at our
institution undergo cEEG monitoring, which therefore
does not represent a selection bias. The use of outside
hospital records and the accuracy of patient records
kept over such a prolonged time span may introduce
information bias.
Conclusions
Our study confirms that SRSE carries a poor prognosis
but underlying catastrophic etiology was the only variable
predictive of poor outcome in our cohort. CIV-PTB
appears relatively safe to use in the ICU setting except
in circumstances of acute hemodynamic instability. cIV-
PTB is very effective to treat SRSE: 90% of our cohort
were seizure-free after treatment with cIV-PTB. With-
drawal seizures were frequent (48% of patients) however,
and cEEG is required to detect and treat them promptly,
and PTB may be helpful in reducing the chance of with-
drawal seizures. Ten percent of patients with SRSE may
recover despite long duration of SE, therefore, the length
of SE by itself should not inform discussions of goals of
care except in cases with catastrophic etiology.
Key messages
 Pentobarbital can be relatively safely used in the
ICU environment.
 Pentobarbital is effective to treat super-refractory
status epilepticus.
 Catastrophic etiology was the only variable associated
with poor outcome. None of the other variables
usually related to outcome in refractory status
epilepticus were associated in our cohort with SRSE.
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